Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis
2022-502647-35-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 27
01
Overview
Phase 2, randomised, double-blind trial of efinopegdutide in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis at Week 52, Percentage of Participants Who Experienced an Adverse Event (AE) and 1 more. Started Aug 2023; status: completed.
02
Drugs
efinopegdutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2022-502647-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502647-35-00.